Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis

OBJECTIVES: ICIs have become the standard treatment for advanced NSCLC patients. Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity and specificity are limited. Therefore, the useful predictive biomarkers of ICI efficacy is urgently needed. BMI is an in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tongtong, Li, Shuluan, Chang, Jianhua, Qin, Yan, li, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594865/
https://www.ncbi.nlm.nih.gov/pubmed/37872469
http://dx.doi.org/10.1186/s12885-023-11512-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594865/
https://www.ncbi.nlm.nih.gov/pubmed/37872469
http://dx.doi.org/10.1186/s12885-023-11512-y

Ejemplares similares